Knowthestock.com
CRSP - CRISPR Therapeutics AG

Sell

Moderate Growth and StableStock Price Very High

44%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 1066.46%
Operating Income turning Positive
Net Income turning Positive
Earnings Per Share (EPS) turning Positive
Net Margin is 45.64%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 26.18
Debt Ratio is 0.11
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.0
Cash Flow is WEAK
Cash from Operations turning Positive
Capital Expenditure is Low
Net Increase in Cash is Negative
Long Term Score Trend is NEUTRAL
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
CRISPR Therapeutics AG (CRSP) - crisprtx.com
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc.CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.
Exchange - NASDAQ
Industry - Biological Product (except Diagnostic) Manufacturing
Sector - Manufacturing
CEO - Samarth Kulkarni
Employees - 304
    Close


Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.